Market Overview
The Global Autoimmune Uveitis Market reached US$ 1.98 Billion in 2024 and is expected to reach US$ 3.31 Billion by 2033, growing with a CAGR of 5.9% during the forecast period 2024-2033.
A rare but potentially dangerous eye disorder known as autoimmune uveitis is characterized by inflammation of the uvea, the central layer of the eye. Autoimmune uveitis can develop in any area of the uvea, which is made up of the iris, ciliary body, and choroid. Because the immune system of the body unintentionally assaults its own healthy eye tissues, causing inflammation, this illness is classified as an autoimmune disease.
Developing specific treatments with fewer side effects and better comprehending the underlying mechanisms of autoimmune uveitis are the main goals of ongoing research.
Market Scope
| Metrics | Details |
| CAGR | YY% |
| Size Available for Years | 2022-2031 |
| Forecast Period | 2024-2031 |
| Data Availability | Value (US$ Mn) |
| Segments Covered | Treatment and Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, South America and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics: Drivers
The Increasing Prevalence of Uveitis
Uveitis is an autoimmune eye illness that only affects about 38 persons in 100,000 people, making it rare. According to Cochrane, a global non-profit organization with headquarters in the UK, uveitis is the sixth most common reason for visual loss in developed nations. It causes 5% to 20% of blindness, especially in those who are working age. Uveitis causes 2.4% to 24% of legal blindness in both developed and developing nations.
As per the International Optholmology in 2021, Although uveitis is regarded as an orphan illness, 40 million individuals globally are seriously affected and go blind as a result of intraocular inflammation, leaving 290 million visually impaired. Uveitis, the fourth most common cause of blindness in adults of working age, affects a higher percentage of young people than elderly people.
Limited Disease Awareness
The general public and healthcare professionals' ignorance about autoimmune uveitis is one of the main barriers to progress in this area. This ailment can present with vague symptoms and is quite uncommon, therefore it frequently goes undetected or is incorrectly diagnosed. This postponed diagnosis may lead to more serious illness and complications.
Although autoimmune uveitis treatment options have improved, there are still just a few medications that are now available. Corticosteroids, immunosuppressive medicines, or biologics are frequently used in modern therapy; nevertheless, these drugs may have serious side effects. To improve patient outcomes, new, more focused medicines must be developed.
Segment Analysis
The global autoimmune uveitis market is segmented based on treatment, distribution channel and region.
The corticosteroids segment accounted for approximately 56.4% of the market share
In terms of uveitis, corticosteroids are a two-edged sword. They are vital in the early stages of uveitis treatment, when prompt management of infammation is necessary. Steroids can be administered locally or systemically, and come in a variety of forms, including topical drops, periocular injections, intravitreal suspensions, and intravitreal implants.
Steroid medications can be used to treat the majority of uveitis cases. Prednisolone is a medication that is frequently used. Steroids act by interfering with the immune system's regular operation so that it no longer secretes the substances that cause inflammation. The type of steroid medication used will frequently depend on the parts of your eye afflicted by uveitis. Steroid medications come in several forms.
Prednisolone acetate suspension, dexamethasone suspension, difuprednate emulsion, loteprednol etabonate suspension, and fuorometholone (FML) suspension are the most popular topical steroid therapy choices. Topical treatment is typically only effective for anterior uveitis and is ineffective for intermediate, posterior, or panuveitis. Periocular injections of corticosteroids can be made either transseptally or into the sub-Tenon's space. Preserved triamcinolone acetonide 40 mg/mL is the standard injection formulation used in the periocular space.
Geographical Analysis
North America accounted for approximately 41.7% of the market share in 2022
North America has been a dominant force in the global autoimmune uveitis market. A series of ocular conditions known as uveitis are characterized by inflammation inside the eye, which can seriously impair vision. According to estimates, it causes 10% of blindness cases in the US, including 30,000 new cases of legal blindness annually. According to the predominant anatomical site of inflammation, uveitis is classified, with anterior uveitis accounting for 50% to 90% of all cases. Despite the fact that uveitis can be infectious or noninfectious, noninfectious uveitis (NIU) is the form that is most frequently seen in the US.
The most recent fuocinolone formulation (Yutiq, Eyepoint Pharmaceuticals, Inc.) is an injectable 0.18-mg implant that has been authorized for the treatment of chronic noninfectious posterior uveitis in the United States. It is similar to the 0.19-mg fuocinolone implant and is made of a polyamide cylinder with the steroid at the center. It costs between 8000 and 9000 US dollars. It is intended to deliver steroid continuously and slowly at a rate of 0.1-0.2 g/day and can last up to 3 years. Its purpose is to prevent rather than treat uveitis flare-ups.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global autoimmune uveitis market. The pandemic caused any autoimmune uveitis therapy clinical trials to be either suspended or postponed. New therapy development and approval were hampered as a result.
During the pandemic, some people with autoimmune uveitis encountered difficulties getting regular eye exams and medical care, which could delay diagnosis and treatment. Telemedicine's adoption was boosted by the epidemic, enabling some patients to continue getting care remotely. Telemedicine used to successfully manage all facets of autoimmune uveitis therapy.
Competitive Landscape
The major global players in the market include AbbVie, Novartis AG, Bausch & Lomb Incorporated, Kiora Pharmaceuticals, Inc., Alimera Sciences, Inc., EyePoint Pharmaceuticals, and Santen Pharmaceutical Co., Ltd. among others.
Why Purchase the Report?
- To visualize the global autoimmune uveitis market segmentation based on treatment, distribution channel, and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of autoimmune uveitis market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global autoimmune uveitis market report would provide approximately 46 tables, 53 figures, and 186 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
